CORDIS
EU research results

CORDIS

English EN
Blood test for clinical therapy guidance of non-small cell lung cancer patients

Blood test for clinical therapy guidance of non-small cell lung cancer patients

Objective

Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) – i.e., patients with mutation(s) in EGFR gene should receive a EGFR-Tyrosine Kinase Inhibitor (TKI) drug (e.g. afitinib) treatment; while those that do not present mutations in such gene, should be treated with chemotherapy. Currently, the laboratories use PCR and Sanger sequencing technologies to perform the EGFR analysis from tumour biopsies - Fixed Paraffin Embedded (FFPE) samples. Still, some patients (e.g., 30% in UK) may never get histological confirmation because they are too sick to make a biopsy. Furthermore, the results obtained with current methods still present low quality, mainly due to poor quality/low yield of DNA extracted from FFPE samples. The FP7 LungCARD project (www.lungcard.eu) has developed and demonstrated a LungCARD system - an automatic system composed by microfluidic chip and chip analyser - that allows to capture circulating tumour cells (CTCs) from blood samples, amplify by multiplex PCR and detect EGFR mutations, including also a software for data analysis and report. Although this new blood test has proven to be faster, cost-effective and human error-free, the detection of somatic mutations in EGFR gene at frequencies lower than 20% is still a weak point.
Therefore, the main project’s goal is to benefit from this technology, through the development, improvement, integration and validation of the LungCARD system with NGS workflow and development of a software for automatic reporting clinical results. However, LungCARD project aims to go further, by putting together a global and unique network of multidisciplinary scientists for exchange of knowledge and research training focused on non-small cell lung cancer.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA

Address

Rua Dos Inventores S/N Edificio Madan Parque Salas 2.18 E 2.19
2825 182 Caparica

Portugal

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 450 000

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY OF HULL

United Kingdom

EU Contribution

€ 180 000

GENOLOGICA MEDICA SL

Spain

EU Contribution

€ 85 500

INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE

Serbia

EU Contribution

€ 18 000

GENETIKS SAGLIK HIZMETLERI TICARETLIMITED SIRKETI

Turkey

EU Contribution

€ 22 500

UNIWERSYTET JAGIELLONSKI

Poland

EU Contribution

€ 40 500

FUNDACAO DA FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA FP

Portugal

FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS

Portugal

EU Contribution

€ 180 000

Partners (9)

Sort alphabetically

Expand all

UNIVERSIDAD SAN MARTIN DE PORRES ASOCIACION

Institut Pasteur Du Maroc

UNIVERSITE HASSAN II DE CASABLANCA

PARSEQ LAB CO LTD

FEDERAL UNIVERSITY OF AGRICULTURE ABEOKUTA

RESPUBLIKA ONKOLOGIYA ILMIY MARKAZI

UNIVERSITY OF TECHNOLOGY SYDNEY

Sloan-Kettering Institute for Cancer Research CORPORATION

MILLI ONKOLOGIYA MERKEZI

Project information

Grant agreement ID: 734790

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 1 039 500

  • EU contribution

    € 976 500

Coordinated by:

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA

Portugal